New York State Common Retirement Fund Sells 28,440 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Common Retirement Fund lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 28.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 72,315 shares of the company’s stock after selling 28,440 shares during the period. New York State Common Retirement Fund owned about 0.22% of TransMedics Group worth $4,509,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after acquiring an additional 10,106 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its holdings in TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after acquiring an additional 32,605 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares in the last quarter. Baillie Gifford & Co. raised its holdings in TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after acquiring an additional 34,947 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TMDX. Canaccord Genuity Group dropped their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

Insider Activity

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.00% of the stock is owned by company insiders.

TransMedics Group Price Performance

TransMedics Group stock opened at $76.32 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The stock’s 50 day moving average is $67.81 and its 200-day moving average is $101.62. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of 81.19 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.